***Background.*** It has been observed that immune responses to vaccination can vary between populations, in particular that immune responses to *Haemophilus influenzae* type b (Hib) vaccines are lower in certain ethnic groups. This study was undertaken to assess the immune response of Canadian Aboriginals (First Nations, Inuit, Métis) to the Hib and hepatitis B virus (HBV) components of the combined hexavalent diphtheria, tetanus, acellular pertussis, HBV, inactivated poliovirus and Hib vaccine (DTPa-HBV-IPV/Hib; GlaxoSmithKline Vaccines).

***Methods.*** Phase IV, open-label, parallel-group study conducted at 3 centers in Canada (NCT00753649). Healthy Aboriginal and non-Aboriginal infants received DTPa-HBV-IPV/Hib at 2, 4 and 6 months of age. Immune responses to Hib polyribosyl ribitol phosphate (PRP) and HBV surface antigen (HBs) were measured 1 month post-dose 3. Medically-attended and serious adverse events (MAAEs/SAEs) were recorded up to 1 month post-dose 3.

***Results.*** Seroprotection against Hib and HBV, 1 month post-dose 3, was comparable in the 94 Aboriginal and 107 non-Aboriginal infants included in the per-protocol analysis (Table). Anti-PRP antibody geometric mean concentrations (GMCs) were 1.7 fold higher in Aboriginal infants (Table).

###### 

Seroprotection rates and GMCs for Hib and HBV, with 95% confidence intervals

                                    Aboriginal                    Non-Aboriginal
  ------------- ------------------- ----------------------------- -----------------------------
  **Hib PRP**   **% ≥0.15 µg/ml**   **97.9** (92.5--99.7)         **99.1** (94.9--100)
                **% ≥1 µg/ml**      **88.3** (80.0--94.0)         **85.0** (76.9--91.2)
                **GMC (µg/ml)**     **6.1** (4.5--8.3)            **3.5** (2.7--4.5)
  **HBs**       **% ≥10 mIU/ml**    **100** (96.0--100)           **100** (96.5--100)
                **GMC (mIU/ml)**    **1797.9** (1375.1--2350.7)   **1544.4** (1210.4--1970.5)

23.2% Aboriginal and 17.0% non-Aboriginal infants recorded MAAEs. 7 SAEs (bronchiolitis, pyrexia, bacterial pneumonia, respiratory syncytial virus infection and 3 cases of convulsion) were recorded in 6 Aboriginal infants; only 1 case (pyrexia) was assessed as vaccine-related; all SAEs had resolved by study end.

***Conclusion.*** 3-dose primary vaccination with DTPa-HBV-IPV/Hib elicited immune responses to the Hib and HBV antigens that were at least as high in Aboriginal as in non-Aboriginal Canadian infants. No safety concerns were identified.

***Disclosures.*** **D. W. Scheifele**, GlaxoSmithKline Vaccines: Grant Investigator, Research grant **M. Ferguson**, GlaxoSmithKline: Employed as an investigator at Colchester Research Group, which conducts multiple clinical trials with companies including GSK. PI in this study. My wife, Dr. Linda Ferguson, is CEO/Owner of CRG which has conducted clinical trials with multiple sponsors over the last 10 years; she has also received renumeration to present papers at conferences and discussions. **D. Assudani**, GlaxoSmithKline: Employee, Salary **S. Kuriyakose**, GlaxoSmithKline Pharmaceuticals: Employee, Salary **O. Van Der Meeren**, GlaxoSmithKline: Employee and Shareholder, Salary **H. H. Han**, GlaxoSmithKline: Employee and Shareholder, Salary

[^1]: **Session:** 128. Vaccines: Pertussis

[^2]: Friday, October 10, 2014: 12:30 PM
